3.0
18. Juni 2008
Ehemaliger Mitarbeiter
Nutley, NJ
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Large company with plenty of funds available for investment or acquisition. Drugs will receive national and international attention - even if that attention is primarily negative in recent years.
Kontras
Senior management (NAOC) has very little idea of how to actually run a successful sales organization. They get bogged down in the task-oriented society where everyone at Nutley is busy CYA. I can't believe more heads didn't roll after the horrid way they handled Cera in the United States. Plan B? No, we don't need a Plan B. If Actemra hits a few snags (and why wouldn't it?) plan on Roche NA being significantly smaller in 2010 than it was in 2007.